PDF电子书：Synthetic Messenger RNA and Cell Metabolism Modulation (Springer MMB-

xyklmu

5 S4 D5 K: w/ c: b
! s) A4 V) J# U- R4 Z[hide][/hide]2 M6 J8 c5 f4 `3 q

' b  r: A8 g& t. v0 K4 m' v; h* r/ z8 }0 v
Synthetic Messenger RNA
+ W4 @  c% ^2 S  d0 ^3 uand Cell Metabolism Modulation
6 V' m# V; I# O0 h+ K8 o# |Methods and Protocols" [2 C! Q' Z; j9 P) A% |7 g
Edited by- m* \9 N" [4 F( X7 Q( @9 s
Peter M. Rabinovich
% p0 X/ S8 F; w/ `: UDepartment of Genetics, The Anlyan Center, Yale School of Medicine,
% R% s, o; o1 [; L( NNew Haven, Connecticut, USA
( D% a  F+ {% y3 l
1 z2 y/ Y7 \# ~6 p1 W# F1 W  t1 U, }' [* |8 Q
Contents- }* k+ Q, y) j& p' W
Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
; [4 c2 g( O  L" {5 L; LContributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix9 g' }5 }+ u4 e) ]* h
PART I mRNA SYNTHESIS, PURI FI CATION, AND TRANSFER1 B* s# n9 L3 L
1 Cell Engineering with Synthetic Messenger RNA . . . . . . . . . . . . . . . . . . . . . . 3
+ V" E& y3 a5 l7 S1 k  QPeter M. Rabinovich and Sherman M. Weissman2 Q' V1 O" g- t4 K/ S3 X
2 In Vitro Transcription of Long RNA Containing Modified Nucleosides . . . . . 299 Z) l$ C( C4 O5 {; h: A
Norbert Pardi, Hiromi Muramatsu, Drew Weissman, and Katalin Karikó
+ ~& G6 q- W# S8 O5 Y8 [3 HPLC Purification of In Vitro Transcribed Long RNA . . . . . . . . . . . . . . . . . . 43
% J% O6 d8 b! O+ v8 Q# {6 g4 {- XDrew Weissman, Norbert Pardi, Hiro Muramatsu, and Katalin Karikó9 K+ B  B7 T2 Y
4 Synthetic mRNAs with Superior Translation and Stability Properties . . . . . . . . 55
% v- l1 a: ~6 X: PEwa Grudzien-Nogalska, Joanna Kowalska, Wei Su, Andreas N. Kuhn,
6 U: p: f8 C3 u) B8 h- |- z, aSergey V. Slepenkov, Edward Darzynkiewicz, Ugur Sahin, Jacek Jemielity,
, q3 \) b# I& T) k2 c; Oand Robert E. Rhoads
! u8 w9 f" e- T& m5 Nonviral, Cationic Lipid-Mediated Delivery of mRNA . . . . . . . . . . . . . . . . . . 73
* c4 b$ X6 |! F7 \5 kJames G. Hecker  d" ?2 o/ F3 X7 [  L# ^3 \
6 Light-Induced mRNA Transfection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89) s$ [! y; w5 R; m, \
Sigurd Leinæs Bøe and Eivind Hovig$ z6 C- L' }; j) G
7 Engineering B Cells with mRNA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
7 I3 L" o( @6 [Jaewoo Lee, David Boczkowski, and Smita Nair
% T; }1 g  L. o6 u8 Programming Human Dendritic Cells with mRNA . . . . . . . . . . . . . . . . . . . . . 111  F8 u  m( ^0 a8 N% M% J! ~" a
Jaewoo Lee, David Boczkowski, and Smita Nair
) E) ^, y& c- _9 z, ?9 Large Volume Flow Electroporation of mRNA: Clinical Scale Process . . . . . . . 127
5 |* d0 I+ R, s& o& XLinhong Li, Cornell Allen, Rama Shivakumar, and Madhusudan V. Peshwa* d7 g  K1 S5 d
10 Retrovirus-Based mRNA Transfer for Transient Cell Manipulation . . . . . . . . . 139
0 r7 e9 M1 E. \# M* h* W" ~- c6 lMelanie Galla, Axel Schambach, and Christopher Baum$ w: m3 ^3 s# U
11 mRNA Delivery to Human Dendritic Cells by Recombinant Yeast
" k2 Q1 f9 ?7 t3 k0 U. Jand Activation of Antigen-Specific Memory T Cells. . . . . . . . . . . . . . . . . . . . . 163
5 w( Z( `9 s5 m2 q# p3 ZFrank Breinig, Tanja Breinig, and Manfred J. Schmitt& @5 E4 ^5 Y2 ?/ O+ h8 ~, l
PART II MODULATION AND MONITORING OF CELL METABOLISM0 m$ R( v$ g0 x, i9 u
12 Nonviral RNA Transfection to Transiently Modify T Cells' O8 ?8 O8 `" n( k# y
with Chimeric Antigen Receptors for Adoptive Therapy . . . . . . . . . . . . . . . . . 187
0 J  K2 f* O  |6 w/ y% [Tobias Riet, Astrid Holzinger, Jan Dörrie, Niels Schaft, Gerold Schuler,
( z9 o5 O; E5 C) b2 ~1 Yand Hinrich Abken% q( g6 S0 |. [
13 Natural Killer Cell Reprogramming with Chimeric Immune Receptors . . . . . . 203+ a5 s4 o1 z$ A6 D7 [4 D6 t
Noriko Shimasaki and Dario Campana, H# ~* J6 y# D2 c
viii Contents! ~' b% @$ B& r8 i. I
14 Reprogramming to Pluripotency and Differentiation of Cells
5 K9 z4 p- N$ F  l& Z% v% ?( E0 bwith Synthetic mRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
$ B: P% O6 Z. U; w! R% BPeizhe Wang and Jie Na
- d1 `9 z0 O- v) W- E15 Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro2 D8 D  E4 t) Q5 @( a
and In Vivo Preclinical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235
2 I# L" }# }0 r/ z# _/ QMustafa Diken, Sebastian Kreiter, Abderraouf Selmi, Özlem Türeci,# Z, J) t$ U; _- Y4 Y  m. i
and Ugur Sahin  T! f* ^: B$ Q, `. [7 ^. _% V
16 Mannosylated and Histidylated LPR Technology for Vaccination4 l/ ^3 y# V, m
with Tumor Antigen mRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247
% J7 a  d3 ]9 WChantal Pichon and Patrick Midoux
# a7 h/ n7 X* w# z3 q) T/ G3 ?/ z17 Analysis of Survivin-Speci fi c T Cells in Breast Cancer Patients
* f3 P# j. }. }% _Using Human DCs Engineered with Survivin mRNA . . . . . . . . . . . . . . . . . . . 275- V, R' p$ g3 p
Özcan Met and Inge Marie Svane
+ P+ E0 f5 x6 u. Z18 mRNA Electroporation as a Tool for Immunomonitoring . . . . . . . . . . . . . . . . 293( w  b( f* G! s6 e! |
Nathalie Cools, Kirsten Van Camp, Viggo Van Tendeloo, and Zwi Berneman7 ]$ q. m3 S8 U3 W  h' x
19 mRNA PCR-Based Epitope Chase Method . . . . . . . . . . . . . . . . . . . . . . . . . . . 305
, e9 e) l& k# |4 o9 x# KJean-Daniel Doucet, Dominique Gauchat, and Réjean Lapointe! i3 Z  d. G3 Z2 y& Y
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321* o$ D2 P. p6 g1 f- P* h0 ?8 b" y
8 x' H9 {4 t5 ?' v, ~' E8 T

/ }0 V' f  T4 ^# ^/ Q( s

命运的宠儿

应该加分  

科研人

干细胞之家

求索迷茫

原来这样也可以  

leeking

先看看怎么样！  

hmhy

胚胎干细胞

ladybird

貌似我真的很笨????哎  

hmhy

顶一个先  

frogsays

胚胎干细胞

剑啸寒

今天没事来逛逛，看了一下，感觉相当的不错。